Delving into the Latest Updates on Chengdu Lingtai Krypton Biotechnology Co., Ltd with Synapse

Overview

Tags

Nervous System Diseases

Neoplasms

Immune System Diseases

lncRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	3
Neoplasms	3
Immune System Diseases	1

Top 5 Drug Type	Count

lncRNA	6

AbstractInhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and excessive inflammation is the current task in the prevention and treatment of COVID-19. Here, we designed a dual-function circular aptamerASO chimera (circSApt-NASO) to suppress SARS-CoV-2 replication and inflammation. The chemically unmodified circSApt-NASO exhibited high serum stability by artificial cyclization, significantly enhancing the utility of oligonucleotides. It presents great efficiency in knocking down, demonstrating the superiority of the circular ASO as a novel tool for sequence-specific silencing of gene expression. Furthermore, we propose and demonstrate that the SApt binding to spike protein enables the chimera to be efficiently delivered into the susceptible host cells expressing ACE2 along with the infection of SARS-CoV-2. At high concentrations of SARS-CoV-2, the efficiency of targeted delivery of circSApt-NASO can even be compared to transfection. Among them, the anti-spike aptamer (SApt) that blocks the Spike-TLR4 interaction potently inhibits spike-induced inflammation. The NASO targeting to silence N genes not only display robust anti-N-induced inflammatory activity, but also achieve efficient inhibition of SARS-CoV-2 replication. Therefore, benefiting from the high stability of the cyclization, anti-spike aptamer-dependent and viral infection-mediate targeted delivery, the circSApt-NASO displays robust potential against authentic SARS-CoV-2 and Omicron (B.1.1.529), providing a promising specific anti-inflammatory and anti-proliferative reagent for therapeutic COVID-19 based on the oligonucleotide therapeutics strategy.

100 Deals associated with Chengdu Lingtai Krypton Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Chengdu Lingtai Krypton Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

4

Preclinical

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LT-010	Neoplasms More	Preclinical
LT-011	Glioma More	Preclinical
LT-006	Autoimmune Diseases More	Preclinical
LT-002	Neoplasms More	Preclinical
LT-013	Central Nervous System Diseases More	Discovery